S. Agresta

发表

Current issues in adolescent and young adult cancer survivorship.

H. Soliman, S. Agresta, 2008, Cancer control : journal of the Moffitt Cancer Center.

Prospective serial evaluation of 2-hydroxyglutarate, during treatment of newly diagnosed acute myeloid leukemia, to assess disease activity and therapeutic response.

A. Iafrate, D. Neuberg, K. Yen, 2012, Blood.

AG-120, an Oral, Selective, First-in-Class, Potent Inhibitor of Mutant IDH1, Reduces Intracellular 2HG and Induces Cellular Differentiation in TF-1 R132H Cells and Primary Human IDH1 Mutant AML Patient Samples Treated Ex Vivo

Hua Yang, K. Yen, O. Bernard, 2014 .

AG-221, an Oral, Selective, First-in-Class, Potent Inhibitor of the IDH2 Mutant Metabolic Enzyme, Induces Durable Remissions in a Phase I Study in Patients with IDH2 Mutation Positive Advanced Hematologic Malignancies

Manish R. Patel, I. Flinn, R. Collins, 2014 .

Effect of itraconazole, food, and ethnic origin on the pharmacokinetics of ivosidenib in healthy subjects

Hua Yang, C. Prakash, S. Agresta, 2019, European Journal of Clinical Pharmacology.

A small molecule inhibitor of mutant IDH2 rescues cardiomyopathy in a D-2-hydroxyglutaric aciduria type II mouse model

A. Kernytsky, Yaguang Si, S. Gross, 2016, Journal of Inherited Metabolic Disease.

Clinical pharmacokinetics and pharmacodynamics of ivosidenib in patients with advanced hematologic malignancies with an IDH1 mutation

Hua Yang, C. Dinardo, S. de Botton, 2020, Cancer Chemotherapy and Pharmacology.

Rhabdomyosarcoma of the maxillary gingiva.

B. Neville, J. D. Barnes, A. Chi, 2007, Journal of periodontology.

A Phase II Study of Trastuzumab-DM1 (T-DM1), a Novel HER2 Antibody–Drug Conjugate, in HER2+ Metastatic Breast Cancer (MBC) Patients Previously Treated with Conventional Chemotherapy, Lapatinib and Trastuzumab.

H. Rugo, P. LoRusso, L. Amler, 2009 .

Enasidenib in mutant IDH2 relapsed or refractory acute myeloid leukemia.

I. Flinn, R. Collins, P. Vyas, 2017, Blood.

Evaluation of Pharmacokinetic-Pharmacodynamic (PKPD) Relationship of an Oral, Selective, First-in-Class, Potent IDH2 Inhibitor, AG-221, from a Phase 1 Trial in Patients with Advanced IDH2 Mutant Positive Hematologic Malignancies

Hua Yang, K. Yen, Fang Wang, 2014 .

AG-221, an Oral, Selective, First-in-Class, Potent IDH2-R140Q Mutant Inhibitor, Induces Differentiation in a Xenotransplant Model

P. Opolon, Hua Yang, K. Yen, 2014 .

Phase I study of AG-120, an IDH1 mutant enzyme inhibitor: Results from the cholangiocarcinoma dose escalation and expansion cohorts.

E. Maher, A. Zhu, G. Abou-Alfa, 2017 .

Phase II study of sunitinib malate (SM) in subjects with metastatic and/or surgically unresectable non-GIST soft tissue sarcomas

C. Williams, D. Sullivan, C. Garrett, 2008 .

Enasidenib Monotherapy Is Effective and Well-Tolerated in Patients with Previously Untreated Mutant- IDH2 (m IDH2) Acute Myeloid Leukemia (AML)

R. Collins, H. Kantarjian, M. Tallman, 2017 .

Molecular Profiling and Relationship with Clinical Response in Patients with IDH1 Mutation-Positive Hematologic Malignancies Receiving AG-120, a First-in-Class Potent Inhibitor of Mutant IDH1, in Addition to Data from the Completed Dose Escalation Portion of the Phase 1 Study

I. Flinn, R. Collins, A. Derti, 2015 .

Effect of itraconazole, food, and ethnic origin on the pharmacokinetics of ivosidenib in healthy subjects

C. Prakash, S. Agresta, Apinya Vutikullird, 2019, European Journal of Clinical Pharmacology.

Durable Remissions with Ivosidenib in IDH1‐Mutated Relapsed or Refractory AML

R. Collins, S. Choe, Hua Yang, 2018, The New England journal of medicine.

HER2-targeted liposomal doxorubicin displays enhanced anti-tumorigenic effects without associated cardiotoxicity.

U. Nielsen, B. Hendriks, P. Zandstra, 2012, Toxicology and applied pharmacology.

Targeted Inhibition of Mutant IDH2 in Leukemia Cells Induces Cellular Differentiation

Fang Wang, Erica Hansen, Francesco G. Salituro, 2013, Science.

IDH2 mutation-induced histone and DNA hypermethylation is progressively reversed by small-molecule inhibition.

Wei Liu, Fang Wang, Hua Yang, 2014, Blood.

Phase I Study of the Mutant IDH1 Inhibitor Ivosidenib: Safety and Clinical Activity in Patients With Advanced Chondrosarcoma.

S. Choe, K. Yen, O. Mir, 2020, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Isocitrate dehydrogenase 1 (IDH1) mutation in breast adenocarcinoma is associated with elevated levels of serum and urine 2-hydroxyglutarate.

K. Yen, A. Bardia, A. Fathi, 2014, The oncologist.

Safety and activity of ivosidenib in patients with IDH1-mutant advanced cholangiocarcinoma: a phase 1 study.

E. Maher, S. Choe, A. Zhu, 2019, The lancet. Gastroenterology & hepatology.

Circulating Oncometabolite 2-Hydroxyglutarate Is a Potential Surrogate Biomarker in Patients with Isocitrate Dehydrogenase-Mutant Intrahepatic Cholangiocarcinoma

Jeffrey W. Clark, A. Iafrate, D. Christiani, 2014, Clinical Cancer Research.

Circulating Oncometabolite 2-Hydroxyglutarate Is a Potential Surrogate Biomarker in Patients with Isocitrate Dehydrogenase-Mutant Intrahepatic Cholangiocarcinoma

Jeffrey W. Clark, A. Iafrate, D. Christiani, 2014, Clinical Cancer Research.

Enasidenib in mutant IDH 2 relapsed or refractory acute myeloid leukemia

I. Flinn, P. Vyas, K. Yen, 2017 .

Phase II study of sunitinib malate, a multitargeted tyrosine kinase inhibitor in patients with relapsed or refractory soft tissue sarcomas. Focus on three prevalent histologies: Leiomyosarcoma, liposarcoma and malignant fibrous histiocytoma

Gang Han, Christopher Garrett, Michael J Schell, 2011, International journal of cancer.

Clonal heterogeneity of acute myeloid leukemia treated with the IDH2 inhibitor enasidenib

P. Vyas, K. Yen, R. Levine, 2018, Nature Medicine.

Phase 1 Single‐ and Multiple‐Ascending‐Dose Randomized Studies of the Safety, Pharmacokinetics, and Pharmacodynamics of AG‐348, a First‐in‐Class Allosteric Activator of Pyruvate Kinase R, in Healthy Volunteers

C. Kung, Hua Yang, M. Goldwasser, 2018, Clinical pharmacology in drug development.

Enasidenib, an inhibitor of mutant IDH2 proteins, induces durable remissions in older patients with newly diagnosed acute myeloid leukemia

R. Collins, H. Kantarjian, M. Tallman, 2019, Leukemia.

Abstract CT103: Clinical safety and activity in a phase I trial of AG-221, a first in class, potent inhibitor of the IDH2-mutant protein, in patients with IDH2 mutant positive advanced hematologic malignancies

I. Flinn, Hua Yang, R. Levine, 2014 .

Therapeutic potential of directed tyrosine kinase inhibitor therapy in sarcomas.

V. Sondak, Audrey C Shor, S. Agresta, 2008, Cancer control : journal of the Moffitt Cancer Center.

ClarIDHy: A phase 3, multicenter, randomized, double-blind study of AG-120 vs placebo in patients with an advanced cholangiocarcinoma with an IDH1 mutation.

A. Zhu, M. Borad, G. Abou-Alfa, 2017 .

Ivosidenib (AG‐120) in Mutant IDH1 Relapsed/Refractory Acute Myeloid Leukemia: Results of a Phase 1 Study: AML‐221

R. Collins, S. Choe, Hua Yang, 2018, Clinical Lymphoma Myeloma and Leukemia.

Ivosidenib (AG-120) in Mutant IDH1 AML and Advanced Hematologic Malignancies: Results of a Phase 1 Dose Escalation and Expansion Study

R. Collins, K. Yen, H. Kantarjian, 2017 .

Ivosidenib induces deep durable remissions in patients with newly diagnosed IDH1-mutant acute myeloid leukemia.

S. Choe, K. Yen, H. Kantarjian, 2019, Blood.

Isocitrate dehydrogenase 1 and 2 mutations, 2‐hydroxyglutarate levels, and response to standard chemotherapy for patients with newly diagnosed acute myeloid leukemia

A. Iafrate, D. Neuberg, Hua Yang, 2018, Cancer.

Practical issues of intraoperative frozen section diagnosis of bone and soft tissue lesions.

David Cheong, Marilyn M Bui, M. Bui, 2008, Cancer control : journal of the Moffitt Cancer Center.

Abstract PL04-05: The first reported results of AG-120, a first-in-class, potent inhibitor of the IDH1 mutant protein, in a Phase I study of patients with advanced IDH1-mutant solid tumors, including gliomas

E. Maher, P. Wen, T. Cloughesy, 2015 .

Characteristics, clinical outcome, and prognostic significance of IDH mutations in AML

M. Konopleva, H. Kantarjian, G. Garcia-Manero, 2015, American journal of hematology.

Clinical Implications of Pathophysiological and Demographic Covariates on the Population Pharmacokinetics of Trastuzumab Emtansine, a HER2‐Targeted Antibody‐Drug Conjugate, in Patients With HER2‐Positive Metastatic Breast Cancer

P. LoRusso, M. Beeram, S. Girish, 2012, Journal of clinical pharmacology.

Serum 2-hydroxyglutarate levels predict isocitrate dehydrogenase mutations and clinical outcome in acute myeloid leukemia.

D. Margolis, O. Abdel-Wahab, K. Yen, 2012, Blood.

Longitudinal Pharmacokinetic/Pharmacodynamic Profile of AG-120, a Potent Inhibitor of the IDH1 Mutant Protein, in a Phase 1 Study of IDH1-Mutant Advanced Hematologic Malignancies

Hua Yang, S. Agresta, K. Le, 2015 .

Evaluation of the Pharmacokinetics of AG-221, a Potent Mutant IDH2 Inhibitor, in Patients with IDH2-Mutation Positive Advanced Hematologic Malignancies in a Phase 1/2 Trial

Hua Yang, E. Attar, S. Agresta, 2015 .

mutations and clinical outcome in acute myeloid leukemia Serum 2-hydroxyglutarate levels predict isocitrate dehydrogenase

D. Margolis, O. Abdel-Wahab, K. Yen, 2013 .

Clinical pharmacokinetics and pharmacodynamics of ivosidenib, an oral, targeted inhibitor of mutant IDH1, in patients with advanced solid tumors

P. Wen, I. Mellinghoff, Hua Yang, 2019, Investigational New Drugs.

Pharmacokinetics, absorption, metabolism, and excretion of [14C]ivosidenib (AG-120) in healthy male subjects

Hua Yang, C. Prakash, S. Agresta, 2019, Cancer Chemotherapy and Pharmacology.

Ivosidenib (AG-120) Induced Durable Remissions and Transfusion Independence in Patients with IDH1-Mutant Untreated AML: Results from a Phase 1 Dose Escalation and Expansion Study

S. Choe, K. Yen, H. Kantarjian, 2018, Blood.

A phase II study of trastuzumab-DM1 (T-DM1), a HER2 antibody-drug conjugate (ADC), in patients (pts) with HER2+ metastatic breast cancer (MBC): Final results.

M. Birkner, H. Burris, C. Vogel, 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Ivosidenib (AG-120) Induced Durable Remissions and Transfusion Independence in Patients with IDH1-Mutant Relapsed or Refractory Myelodysplastic Syndrome: Results from a Phase 1 Dose Escalation and Expansion Study

S. Choe, K. Yen, H. Kantarjian, 2018, Blood.

L05.04MUTATION-SELECTIVE IDH INHIBITORS MEDIATE HISTONE AND DNA METHYLATION CHANGES

K. Yen, S. Agresta, 2013 .

A phase I/II study of MM-111, a novel bispecific antibody that targets the ErB2/ErB3 heterodimer, in combination with trastuzumab in advanced refractory HER2-positive breast cancer.

J. Murray, N. Gabrail, P. Ryan, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

DRIVE PK: A Phase 2 Trial of AG-348 in Patients with Pyruvate Kinase Deficiency

C. Kung, Hua Yang, B. Silver, 2015 .

1LBA Clinical safety and activity in a phase I trial of AG-120, a first in class, selective, potent inhibitor of the IDH1-mutant protein, in patients with IDH1 mutant positive advanced hematologic malignancies

Hua Yang, M. Tallman, R. Stone, 2014 .

Sunitinib treatment of pediatric metastatic GIST after failure of imatinib.

G. Demetri, C. Corless, C. Garrett, 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

AG-221 Offers a Survival Advantage In a Primary Human IDH2 Mutant AML Xenograft Model

S. Choe, Hua Yang, K. Yen, 2013 .

Clonal heterogeneity of acute myeloid leukemia treated with the IDH2 inhibitor enasidenib

P. Vyas, K. Yen, R. Levine, 2018, Nature Medicine.

P. LoRusso, M. Beeram, S. Girish, 2012, Journal of clinical pharmacology.

4 Bone Sarcoma ... Turning the Corner

Shawna V. Hudson, V. Sondak, G. Bepler, 2008 .

Abstract 2296: IDH2 mutation induced histone and DNA hypermethylation is progressively reversed by small molecule inhibition

A. Kernytsky, W. Liu, Stuart Murray, 2014 .